Navigation
Navigation

Capricorn Health-tech Fund

The Capricorn Health-tech Fund (CHF) focuses on human health-technology investments. Health-technologies relate to the prevention, the diagnosis and the treatment of diseases.

Confo Therapeutics awarded € 1 million VLAIO grant for pre-clinical development of CFTX-1554, an AT2R modulator for the treatment of neuropathic pain

News
- 30/03/2021
Ghent, Belgium: 30 March 2021 – Confo Therapeutics announced today that it has been awarded a € 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development of CFTX-1554, Confo’s…
Read more

Nexstim gives an update on its promising treatment results of Major Depressive Disorder

News
- 12/03/2021
Helsinki, Finland: 12 March 2021 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) reports very promising clinical outcomes of the 159 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD).…
Read more

Team
Dr Jos B. Peeters
Chairman Executive Committee - Venture Capital, IT
Dr Katya Smirnyagina
Executive Director Capricorn Health-tech Fund

Portfolio

Success stories

Ogeda

Ogeda [Belgium] is a drug development company with a chemistry service business focusing on discovery of small molecules targeting GPCRs.